SMAD4 and lung carcinoma: Co-occurrence of expression of the GI markers CDH17, CDX2, CK20, GPA33, MUC2, and SATB2 (i.e., MUC6 and SMAD4 excluded of the investigated markers) for subgroups of lung cancer and pulmonary metastases are presented in Table 4 and Fig. 3.